Phase 2 Cystic Fibrosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Part 1 (Healthy Volunteers):
- You are a healthy adult (male or female) between 18 and 55 years old
- You weigh at least 50 kg and your Body Mass Index (BMI) falls between 16 and 32
- Your lung function test shows your lungs are working at least 80% as well as expected for someone your age and size
- A doctor has reviewed your health history, blood tests, heart tracing, and physical exam and considers you to be in good general health
- You understand and are willing to follow all study procedures as outlined in the consent form
Parts 2 & 3 (People with Cystic Fibrosis):
- You have a confirmed diagnosis of Cystic Fibrosis (CF)
- Your lung function is between 50% and 100% of what is expected for your age, sex, and height
- You have CF gene mutations on both copies of the gene that do not respond to CFTR modulator treatments, OR you are eligible for CFTR modulator treatments but cannot take them due to side effects or medical reasons that prevent their use
Who may not be able to join:
Part 1 (Healthy Volunteers):
- You have a significant medical, surgical, or mental health condition, either currently or in the past
- Your blood pressure while lying down is higher than 150 (top number) or 90 (bottom number) after resting for at least 5 minutes
- Your blood test results at the screening visit come back abnormal
- You currently smoke, use nicotine products, or have done so in the past 6 weeks, or you are a former smoker with a long history of heavy smoking (more than 10 "pack years")
Parts 2 & 3 (People with Cystic Fibrosis):
- You have serious liver disease with complications, or moderate to severe liver damage (confirm with trial site)
- You have had a chest or airway infection, a worsening of your lung symptoms, or a change in your lung-related medicines (including antibiotics) in the 4 weeks before starting the study
- You currently have a lung infection caused by certain bacteria known to cause faster lung decline (confirm with trial site)
- The level of oxygen in your blood measured without any oxygen support is below 94% at your screening visit
- You have taken a CF modulator medicine such as Kalydeco, Trikafta, Symdeko, Orkambi, or Alyftrek within the 12 weeks before your screening visit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John Matthews, MBBS, MCRP, PhD, ReCode Therapeutics, Inc.
Phone: 650-629-7900
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1: The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).; Part 2: The number of participants with CF with AEs and SAEs.; Part 3: The number of participants with CF with AEs and SAEs.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.